Halozyme Therapeutics Inc
HALO
$116.82+6.57%
End of day · as of Oct 14, 2026, 8:00 PM ET
Mkt cap
$7.10B
EV/Sales
6.52
P/E ratio
N/A
FY2025 Revenue
$1.40B
EPS (TTM)
$3.41
Gross Margin (FY2025)
83.62%
Profit Margin (FY2025)
22.69%
Beta
1.19
Div yield
N/A
Sector
Healthcare
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B.
Use this HALO research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full HALO income, balance, and cash tables.
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
Halozyme Therapeutics Inc (HALO) is a biotechnology company in the Healthcare sector.
Latest cached Halozyme Therapeutics Inc (HALO) revenue for Dec 31, 2025 was $1.40B. Net income was $316.9M. Statements: https://lician.com/financials/halo
Halozyme Therapeutics Inc (HALO) market capitalization is $7.10B on the latest cached snapshot.
Halozyme Therapeutics Inc (HALO) cached previous close $109.62; day range $109.90 – $116.82; volume 3,786,164. Session quote: https://lician.com/quote/halo
Halozyme Therapeutics Inc (HALO) latest cached earnings event is "HALO earnings" on Aug 6, 2026. Earnings calendar: https://lician.com/earnings
The latest cached HALO filing is 8-K · Sep 30, 2026. Filings: https://lician.com/sec/halo